FDA Reposts Warning About Pregnancy-Related Risks Associated With Organ Transplant Drugs
Main Category: Pregnancy / ObstetricsAlso Included In: Transplants / Organ Donations
Article Date: 21 May 2008 - 7:00 PDT
|
|
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
FDA on Friday reposted a notice warning that Roche and Novartis drugs prescribed for organ transplant recipients could cause miscarriages and birth defects when used by pregnant women and urged doctors to confirm that transplant patients are not pregnant and are using effective contraception, the AP/Google.com reports. Roche's CellCept and Novartis' Myfortic are used to suppress the body's immune system to avoid organ rejection in people undergoing transplant surgery.
FDA first issued the warning in October 2007. Agency spokesperson Christopher Kelly said that FDA has not received any new reports of pregnancy-related complications but that it was concerned that some physicians might not have seen the initial warning. FDA said most of the reported problems came from women who were taking CellCept before they knew they were pregnant. Some of the women were taking the drug for conditions it was not approved to treat, including rheumatoid arthritis and lupus. A spokesperson for Roche said the company has not received any new reports of miscarriages or birth defects since updating the drug's labeling (Perrone, AP/Google.com, 5/16).
When FDA issued the initial warning, it cited National Transplantation Pregnancy Registry data published in December 2006 of 24 women exposed to CellCept. The women had a total of 33 pregnancies, of which 15 resulted in a miscarriage and 18 in a live birth. Among the 18 live births, four infants had birth defects. According to postmarketing data, which were collected by Roche and involved 77 women who took CellCept, there were 25 miscarriages and 14 birth defects among fetuses and infants (Daily Women's Health Policy Report, 10/31/07).
Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.
© 2008 The Advisory Board Company. All rights reserved.
Visit our pregnancy / obstetrics section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/108178.php>
APA
http://www.medicalnewstoday.com/releases/108178.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



